Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID) by Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D. Danenberg, Narikazu Boku, Takako Eguchi Nakajima

Get full text